A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis

NCT ID: NCT03421145

Last Updated: 2024-10-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-17

Study Completion Date

2019-01-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rinse contains an anti-plaque agent that helps prevent the accumulation of dental plaque associated with gingivitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, single site, randomized, parallel, blinded clinical trial. Subjects will be randomly assigned to one of four treatment groups identified as Product A, Product B, Product C or Product D.

Subjects will be screened for eligibility and entered into a washout period that is at least 7 days, during which time they will be provided with study toothbrush, toothpaste and dental floss. No oral rinses or medication that alters oral tissue health will be used or taken during the washout period. After randomization, the designated rinse will be placed into a non-transparent container so that other subjects and clinical examiners do not see the allocated rinse per the randomization schedule.

Examinations for the clinical endpoints (PI, GI and BI) will be conducted at the baseline, 3-month, and 6-month visits.

Interim visits will be scheduled to review diary, replenish study supplies, check study compliance, etc. Subjects will be provided Colgate Regular toothpaste, dental floss and a soft toothbrush (replaced at 3 months) for use during the 6-month study period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

prospective, randomized, blinded, clinical study to evaluate an oral rinse on plaque and gingivitis
Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
The Principal Investigator and clinical examiners will be blinded to the treatment products. No clinical examiners will see the allocated rinse assigned per the randomization schedule.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3M™ Oral Rinse

Subjects assigned to the Experimental Oral Rinse ('Plaque control device) will swish a volume of 15 mL of the Experimental Rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.

Group Type EXPERIMENTAL

3M™ Oral Rinse

Intervention Type DEVICE

The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).

Vehicle Control Oral Rinse

Vehicle control oral rinse (no active ingredient). Subjects assigned to the Placebo Comparator will swish a volume of 15 mL of the Placebo Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.

Group Type PLACEBO_COMPARATOR

Vehicle Control Oral Rinse

Intervention Type OTHER

The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.

PerioShield™ Oral Health Rinse

Active control predicate device oral rinse ('Plaque control agent') Subjects assigned to the Active Comparator will swish a volume of 10 mL of the Active Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.

Group Type ACTIVE_COMPARATOR

PerioShield™ Oral Health Rinse

Intervention Type DEVICE

PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.

Water

Water sham control oral rinse (not a Plaque control agent) Subjects assigned to the Sham Comparator will swish a volume of 15 mL of the Sham Comparator rinse for 30 seconds followed by expectoration, twice a day (morning and evening), after brushing teeth, for the 6-month duration of the study. They will use the dosing cup provided by the study team to ensure that the proper dose of rinse is used. Subjects will be instructed not to eat or drink for 30 minutes after using the rinse and to complete the subject daily diary.

Group Type SHAM_COMPARATOR

Water

Intervention Type OTHER

Purified bottled water containing no active ingredients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3M™ Oral Rinse

The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).

Intervention Type DEVICE

Vehicle Control Oral Rinse

The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.

Intervention Type OTHER

PerioShield™ Oral Health Rinse

PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.

Intervention Type DEVICE

Water

Purified bottled water containing no active ingredients.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Plaque control device Placebo Comparator Active Comparator Sham Comparator

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects to whom these criteria apply will be entered into the 7-day washout

* Able to understand and willing to sign the Informed Consent
* In good general health ages 18 and older
* Have at least 20 natural teeth, including at least one molar and one premolar in each quadrant but excluding the third molars
* Willing to return to the study facility for scheduled study visits and recalls
* Agree not to use other oral hygiene products (non-study toothpaste, dental floss, mouth rinse, chewing gum)
* Agree not to brush or floss teeth after 10:00 pm the night before and not eat or drink 4 hours before an appointment
* Agree to the study instructions and visit schedule, including no eating or drinking for 4 hours before assessment appointments


* Completed the washout period (at least 7 days) using only the study toothbrush, dental floss and toothpaste
* A qualifying baseline GI of at least 1.0, as determined by the Löe-Silness Gingival Index (GI)

Exclusion Criteria

* Subjects to whom these conditions apply will be excluded:

* A history of antibiotic therapy within the previous 30 days or have a condition that is likely to need antibiotic treatment over the course of the study (eg, cardiac conditions requiring antibiotic prophylaxis such as heart murmurs, pacemakers, or prosthetic heart valves, and prosthetic implants)
* A history of using antimicrobial oral mouth rinse during the past 3 months
* Taking medications which may alter gingival appearance/bleeding
* Use of anticonvulsants, calcium channel blockers, or other medications with side effects known to impact oral health
* Current participation in any other clinical study within the past 30 days
* Reside in the same household with a subject already enrolled in the study
* Dry mouth due to head/neck radiation therapy
* Orthodontic appliances
* Widespread caries or chronic neglect
* Gross pathological changes of oral soft tissues
* Known history of sensitivity to oral hygiene products
* Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive alveolar bone loss)
* Pregnant or nursing or plan to become pregnant within the 6 month study duration
* Medical and oral conditions that, in the investigator's judgment, may compromise the subject's safety or interfere with the conduct and outcome of the study
* Difficult to be compliant with study visits, such as extensive travel commitments or lack of transportation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

3M

INDUSTRY

Sponsor Role collaborator

Solventum US LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Loma Linda Dental Reserach

Loma Linda, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Parameter on plaque-induced gingivitis. American Academy of Periodontology. J Periodontol. 2000 May;71(5 Suppl):851-2. doi: 10.1902/jop.2000.71.5-S.851.

Reference Type BACKGROUND
PMID: 10875689 (View on PubMed)

2. National Institute of Health and Clinical Excellence (NICE). Dental recall interval between routine dental examinations. http://guidance.nice.org.uk/CG19 Clinical Guideline 19; 2004.

Reference Type BACKGROUND

Baehni PC, Takeuchi Y. Anti-plaque agents in the prevention of biofilm-associated oral diseases. Oral Dis. 2003;9 Suppl 1:23-9. doi: 10.1034/j.1601-0825.9.s1.5.x.

Reference Type BACKGROUND
PMID: 12974527 (View on PubMed)

Moran JM. Chemical plaque control--prevention for the masses. Periodontol 2000. 1997 Oct;15:109-17. doi: 10.1111/j.1600-0757.1997.tb00110.x. No abstract available.

Reference Type BACKGROUND
PMID: 9643238 (View on PubMed)

Steinberg D, Feldman M, Ofek I, Weiss EI. Effect of a high-molecular-weight component of cranberry on constituents of dental biofilm. J Antimicrob Chemother. 2004 Jul;54(1):86-9. doi: 10.1093/jac/dkh254. Epub 2004 May 26.

Reference Type BACKGROUND
PMID: 15163648 (View on PubMed)

Li Y, Lee S, Hujoel P, Su M, Zhang W, Kim J, Zhang YP, DeVizio W. Prevalence and severity of gingivitis in American adults. Am J Dent. 2010 Feb;23(1):9-13.

Reference Type BACKGROUND
PMID: 20437720 (View on PubMed)

LOE H, SILNESS J. PERIODONTAL DISEASE IN PREGNANCY. I. PREVALENCE AND SEVERITY. Acta Odontol Scand. 1963 Dec;21:533-51. doi: 10.3109/00016356309011240. No abstract available.

Reference Type BACKGROUND
PMID: 14121956 (View on PubMed)

Talbott K, Mandel ID, Chilton NW. Reduction of baseline gingivitis scores with repeated prophylaxes. J Prev Dent. 1977 Nov-Dec;4(6):28-9. No abstract available.

Reference Type BACKGROUND
PMID: 275491 (View on PubMed)

QUIGLEY GA, HEIN JW. Comparative cleansing efficiency of manual and power brushing. J Am Dent Assoc. 1962 Jul;65:26-9. doi: 10.14219/jada.archive.1962.0184. No abstract available.

Reference Type BACKGROUND
PMID: 14489483 (View on PubMed)

Turesky S, Gilmore ND, Glickman I. Reduced plaque formation by the chloromethyl analogue of victamine C. J Periodontol. 1970 Jan;41(1):41-3. doi: 10.1902/jop.1970.41.41.41. No abstract available.

Reference Type BACKGROUND
PMID: 5264376 (View on PubMed)

Lobene RR, Soparkar PM, Newman MB. Use of dental floss. Effect on plaque and gingivitis. Clin Prev Dent. 1982 Jan-Feb;4(1):5-8. No abstract available.

Reference Type BACKGROUND
PMID: 6980082 (View on PubMed)

Caton JG, Polson AM. The interdental bleeding index: a simplified procedure for monitoring gingival health. Compend Contin Educ Dent (Lawrenceville). 1985 Feb;6(2):88, 90-2. No abstract available.

Reference Type BACKGROUND
PMID: 3871687 (View on PubMed)

13. FDA FOI, 510(k) for Sinclair Pharmaceuticals PMA for Decapinol, Retrieved from http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHFOIAElectronicReadingRoom/UCM237296.pdf

Reference Type BACKGROUND

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan: Protocol with planned Statistical Analysis Plan

View Document

Document Type: Statistical Analysis Plan: Detailed Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EM-11-050003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Experimental Mouthwashes
NCT05121909 COMPLETED PHASE4
Anti-gingivitis Mouthrinse
NCT06048627 COMPLETED PHASE3